In 2023, the global healthcare regulatory affairs outsourcing market was estimated to be valued at USD 2,203.40 million. During the forecast period, the market is likely to garner a moderate CAGR of 6.70%. By 2034, the market is predicted to gain a valuation of USD 4,052.30 million by 2034.
| Report Attribute | Details |
|---|---|
| Estimated Market Value in 2023 | USD 2,203.40 million |
| Expected Market Value in 2024 | USD 2,118.60 million |
| Projected Forecast Value in 2034 | USD 4,052.30 million |
| Anticipated Growth Rate from 2024 to 2034 | 6.70% |
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
Market players are offering healthcare firms with functional outsourcing to enhance efficiency. These outsourcing companies offer the healthcare forms to contract multiple monitors (CRAs), coordinators, senior monitors, and project managers for a particular period of time. This would help them to support the internal resources without the expansion of their own clinical team.
The outsourcing services have dedicated clinical experts working under the project management of the clients. They mostly offer FTE based budgets, with predictable and fixed pricing.
Healthcare companies will have a single point of contact with these outsourcing firms. All the staffing requirements, from changing needs to operational and financial management of the projects, will be taken care of.
The global demand for the healthcare regulatory affairs outsourcing market was estimated to reach a valuation of USD 1,123.80 million in 2018, according to a report from Future Market Insights. From 2018 to 2023, the healthcare regulatory affairs outsourcing market witnessed significant growth, registering a CAGR of 12.10%.
| Historical CAGR from 2018 to 2023 | 12.10% |
|---|---|
| Forecast CAGR from 2024 to 2034 | 6.70% |
The growth of biotechnology and pharmaceutical companies is a major factor driving the healthcare regulatory affairs outsourcing market as they require effective regulatory plans and submissions.
Companies are spending more and more on outsourcing partners for specific regulatory knowledge as they struggle to bring new goods to market. This helps them navigate complex regulatory frameworks, gain a competitive edge, and ensure compliance and timely market entrance
Cost Savings, Increased Efficiency and Regulatory Compliance to Push Companies toward these Services
Companies can avoid the overhead expenses associated with having an in-house regulatory affairs staff. With outsourcing, companies may pay for just the work completed, giving them flexibility.
Efficiency gains are possible through outsourcing. There are various kinds of core and non-core activities within a healthcare company. By outsourcing the non-core activities, companies can devote more time towards the core activities and enhance the efficiency.
With the evolving regulatory framework of various bodies, the healthcare companies find it quite difficult to abide by it all at the same time. They prefer to outsource such responsibilities to a third company that holds better knowledge of all these.
High Initials Costs and Technological Challenges to Restrict Market Growth
Healthcare regulatory affairs outsourcing services have a lot of advantages for the healthcare companies. But there are some serious complications with data too. By outsourcing services, healthcare companies will face a loss of control over their own critical processes.
Companies have to provide the outsourcing forms with their complete set of data, which can lead to patient data leak and vulnerabilities. A lack of direct monitoring and control over outsourced medical billing and collections could make patient data vulnerable. Factors such as these can hinder the global market growth eventually.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
This section focuses on providing detailed analysis of two particular market segments for the healthcare regulatory affairs outsourcing, the dominant service type and the significant end user. The two main segments discussed below are the regulatory writing and publishing service and mid-size pharmaceutical companies.
| Services | Regulatory Writing and Publishing |
|---|---|
| Market Share in 2023 | 33.60% |
In 2023, the regulatory writing and publishing service was estimated to gain a market share of 33.60%. This is because there is a growing need for thorough documentation and submission assistance.
Companies are looking for qualified experts to guarantee correct and timely submissions due to changing legislation and tighter compliance standards. Companies in the healthcare sector can improve productivity, simplify procedures, and successfully comply with regulations by outsourcing these jobs.
| End User | Mid-Sized Pharmaceutical Companies |
|---|---|
| Market Share in 2023 | 29.20% |
In 2023, the mid-size pharmaceutical companies were estimated to be the dominant end user for the healthcare regulatory affairs outsourcing market. They may accelerate product development schedules, handle complicated compliance needs with efficiency, and concentrate resources on key capabilities by outsourcing regulatory affairs.
The ability to obtain expertise catered to their particular requirements is one notable benefit of outsourcing regulatory affairs for mid-sized pharmaceutical companies. This enables them to successfully negotiate complicated regulatory landscapes while concentrating on the core operations. They may now more successfully compete in the market while still adhering to legal requirements due to this.
This section will go into detail on the healthcare regulatory affairs outsourcing markets in a few key countries, including the United States, the United Kingdom, Spain, Thailand and Indonesia. This part will focus on the key factors that are driving up demand in these countries for the healthcare regulatory affairs outsourcing.
| Countries | CAGR from 2024 to 2034 |
|---|---|
| The United States | 3.40% |
| The United Kingdom | 3.80% |
| Spain | 4.40% |
| Thailand | 5.30% |
| Indonesia | 4.50% |
The United States healthcare regulatory affairs outsourcing ecosystem is anticipated to gain a CAGR of 3.40% through 2034. Continuous innovation in healthcare technology necessitates faster regulatory processes in order to bring novel products to market as quickly as possible.
Outsourcing regulatory affairs enables businesses to use professional expertise and resources to speed approvals, assuring rapid market access while conforming to regulatory requirements.
The healthcare regulatory affairs outsourcing market in the United Kingdom is expected to expand with a 3.80% CAGR through 2034. Brexit, the United Kingdom's exit from the European Union, still causes regulations in the healthcare industry to be out of compliance with EU standards.
Companies who operate in both the United Kingdom's and the European Union's markets face difficulties as a result of this possible regulatory divergence since they have to deal with several regulatory regimes.
After Brexit, specialized knowledge becomes necessary to comprehend and abide by the changing British rules. Companies may conveniently acquire this knowledge by outsourcing regulatory affairs, which guarantees that they can maintain compliance and adjust to new needs while concentrating on their core business operations.
The healthcare regulatory affairs outsourcing ecosystem in Spain is anticipated to develop with a 4.40% CAGR from 2024 to 2034.Spain's distinct cultural and linguistic characteristics necessitate specialized expertise for most effective regulatory compliance.Regulatory affairs might be outsourced to companies with local knowledge to enable more efficient understanding and communication of regulations.
The healthcare regulatory affairs outsourcing industry in Thailand is anticipated to reach a 5.30% CAGR from 2024 to 2034. The healthcare industry in Thailand is at present aimed at aligned its regulations with that of the international norms and standards.
This step requires immense expertise and knowledge, pushing them towards outsourcing agencies. Regulatory affairs outsourcing provides access to expert knowledge necessary for effectively navigating these dynamic regulatory regimes.
The healthcare regulatory affairs outsourcing ecosystem in Indonesia is likely to evolve with a 4.50% CAGR during the forecast period.
Indonesia has got certain strict regulatory bodies for various medical devices and pharmaceutical drugs. These regulations are stated by bodies like the National Agency of Drug and Food Control (NADFC) functioning under the Indonesian Ministry of Health (MoH).
In order to comply with the changing regulations from these bodies, companies require investments to overcome the hurdles. Market players in Indonesia, thus, take help from various healthcare companies to get large scale investments to meet regulatory compliance.
Market players are actively offering specialized regulatory assistance to biotechnology, pharmaceutical, and medical device companies within the healthcare regulatory affairs outsourcing market.
They provide proficiency in navigating through intricate regulatory structures, guaranteeing adherence to legal statutes and guidelines, and hastening the approvals for the research and studies.
Companies also provide a variety of services, such as pharmacovigilance, submission preparation, regulatory strategy development, and compliance monitoring. They want to reduce the regulatory restrictions consumers face in order to promote healthcare facilities more efficiently and in conformity with quality standards.
This suggests that the market players are simply aimed at easing down the various restrictions that organizations face due to legal restrictions. The key players in this market include:
Key Development by Market Players
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 6.70% from 2024 to 2034 |
| Market value in 2024 | USD 2,118.60 million |
| Market value in 2034 | USD 4,052.30 million |
| Base Year for Estimation | 2023 |
| Historical Data | 2018 to 2023 |
| Forecast Period | 2024 to 2034 |
| Quantitative Units | USD million for value |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Services, End User, Region |
| Regions Covered | North America; Latin America; Western Europe; Eastern Europe; South Asia and Pacific; East Asia; The Middle East & Africa |
| Countries Profiled |
The United States, Canada, Brazil, Mexico, Germany, The United Kingdom, France, Spain, Italy, Poland, Russia, Czech Republic, Romania, India, Bangladesh, Australia, New Zealand, China, Japan, South Korea, GCC Countries, South Africa, Israel |
| Key Companies Profiled | Accell Clinical Research LLC; Charles River Laboratories; Syneos Health; Laboratory Corporation of America Holdings; ICON PLC.; IQVIA; Medpace, Inc.; PAREXEL International Corporation; Thermo Fisher Scientific Inc. (PPD); Promedica International; WuXi App Tec |
| Customisation Scope | Available on Request |
The healthcare regulatory affairs outsourcing market is expected to garner a 6.70% CAGR from 2024 to 2034.
By 2024, the global healthcare regulatory affairs outsourcing market is likely to gain USD 2,118.60 million.
By 2034, the healthcare regulatory affairs outsourcing market valuation is likely to reach a sum of USD 4,052.30 million.
The healthcare regulatory affairs outsourcing industry in the United States is likely to rise at a 3.40% CAGR during the forecast period.
The regulatory writing and publishing segment is likely to gain traction in the global healthcare regulatory affairs outsourcing market with a 33.60% market share in 2023.
The mid-size pharmaceutical companies are likely to be the dominant end user of healthcare regulatory affairs outsourcing, with a 29.20% market share in 2023.
| Estimated Size (2025) | USD 1,346.8 billion |
| Projected Valuation (2035) | USD 2,153.7 billion |
| Value CAGR (2025 to 2035) | 4.8% |
| CAGR (2023 to 2033) | 7.2% |
|---|---|
| Market Size (2023) | USD 52.877 billion |
| Market Size (2033) | USD 105.753 billion |
| Market Size (2023) | USD 4.2 Billion |
|---|---|
| Market Value (2033) | USD 16.2 Billion |
| Value CAGR (2023 to 2033) | 14.5% |
| Market Size in (2023) | USD 106.0 billion |
|---|---|
| Market Size in (2033) | USD 912.0 billion |
| Market CAGR (2023 to 2033) | 24% |
Explore Healthcare Services Insights
View Reports
Healthcare Regulatory Affairs Outsourcing Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
